PRX Related New Coverage
-
Piper Jaffray Starts Par Pharmaceutical (PRX) at Overweight
-
Piper Jaffray Starts Par Pharmaceutical (PRX) at Overweight
-
JPMorgan Starts Par Pharmaceutical (PRX) at Neutral
-
ThinkEquity Starts Par Pharmaceutical (PRX) at Buy
-
Leerink Swann Starts Par Pharmaceutical (PRX) at Outperform; Under-Appreciated Pipeline
-
UBS Initiates Coverage on Par Pharmaceutical (PRX) with a Buy; Small and Nimble is Interesting To Us
-
UBS Starts Alkermes (ALKS), Par Pharma (PRX) at Buy, Salix Pharma (SLXP) at Neutral
-
RBC Initiates Coverage on Several Drug Makers
-
Needham & Co Initiates Coverage on Drugs - Generic
-
Stanford Starts Par Pharmaceutical (PRX) at Hold
-
Caris Starts Par Pharmaceutical (PRX) at Average
-
JPMorgan Starts Par Pharma (PRX) at Neutral
Back to PRX Stock Lookup
